Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · breast-umap@18

SRR8518204

— · F

3433a5e1-c5a0-56da-86f2-d502ed7326dd

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
F
subtype
F

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • OXIDATIVE_PHOSPHORYLATION+0.470
  • REACTIVE_OXYGEN_SPECIES_PATHWAY+0.450
  • CHOLESTEROL_HOMEOSTASIS+0.420
  • ANDROGEN_RESPONSE+0.390
  • ADIPOGENESIS+0.340
  • FATTY_ACID_METABOLISM+0.320
  • BILE_ACID_METABOLISM+0.310
  • PANCREAS_BETA_CELLS+0.310
  • XENOBIOTIC_METABOLISM+0.300
  • PROTEIN_SECRETION+0.270

Top 10 suppressed

  • INTERFERON_ALPHA_RESPONSE-0.610
  • INTERFERON_GAMMA_RESPONSE-0.540
  • E2F_TARGETS-0.500
  • G2M_CHECKPOINT-0.490
  • IL6_JAK_STAT3_SIGNALING-0.450
  • MITOTIC_SPINDLE-0.400
  • ALLOGRAFT_REJECTION-0.370
  • INFLAMMATORY_RESPONSE-0.350
  • WNT_BETA_CATENIN_SIGNALING-0.340
  • ANGIOGENESIS-0.320

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

9 twins match this tumor's tissue · 1 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1SRR8518189
breast-umap@18
—F0.908
2SRR8943024
bladder-landscape@3
——0.898
3SRR8518177
breast-umap@18
—F0.860
4SRR8518211
breast-umap@18
—C0.850
5TCGA-E2-A1LB-01A-11R-A144-07
breast-umap@18
—F0.839
6SRR8518242
breast-umap@18
—F0.837
7SRR8518413
breast-umap@18
—F0.836
8MBCProject_3946_T5A_RNA
breast-umap@18
—C0.834
9SRR1471817
brain-umap@2
GTEX—0.831
10SRR8518241
breast-umap@18
—F0.829

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 22 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
OXIDATIVE_PHOSPHORYLATION0.470Remibrutinib— uncovered
REACTIVE_OXYGEN_SPECIES_PATHWAY0.450Inavolisib— uncovered
CHOLESTEROL_HOMEOSTASIS0.420Remibrutinib— uncovered
ANDROGEN_RESPONSE0.390Inavolisib— uncovered
ADIPOGENESIS0.340Inavolisib— uncovered
FATTY_ACID_METABOLISM0.320Inavolisib— uncovered
BILE_ACID_METABOLISM0.310Inavolisib— uncovered
PANCREAS_BETA_CELLS0.310Cobimetinib— uncovered
XENOBIOTIC_METABOLISM0.300Inavolisib— uncovered
PROTEIN_SECRETION0.270Remibrutinib— uncovered
PEROXISOME0.200Idelalisib— uncovered
ESTROGEN_RESPONSE_EARLY0.190Inavolisib— uncovered
MTORC1_SIGNALING0.190Inavolisib— uncovered
UNFOLDED_PROTEIN_RESPONSE0.180Idelalisib— uncovered
COAGULATION0.160Binimetinib— uncovered
ESTROGEN_RESPONSE_LATE0.160Idelalisib— uncovered
P53_PATHWAY0.140Idelalisib— uncovered
GLYCOLYSIS0.130Inavolisib— uncovered
DNA_REPAIR0.100Idelalisib— uncovered
PI3K_AKT_MTOR_SIGNALING0.080Inavolisib— uncovered